Stock Track | Sarepta Therapeutics Plunges 5.17% After-Hours on Disappointing Q1 Results and Sharp ELEVIDYS Sales Decline

Stock Track05-07

Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.17% following the release of its first-quarter 2026 financial results.

While the company reported a positive swing to net income and beat earnings expectations, investors reacted negatively to a 2% year-over-year decline in quarterly revenue to $730.8 million. The decline was primarily driven by a sharp 73% decrease in sales of its flagship gene therapy, ELEVIDYS, which fell to $101.97 million. Overall product revenues dropped 46% to $330.5 million.

The significant drop in ELEVIDYS demand is attributed to an updated product label that restricts treatment to ambulatory patients, significantly reducing the total addressable market for the therapy. This follows safety events in the previous year and a regulatory crackdown that led to temporary shipment pauses. Despite collaboration revenue growth from milestone payments, including from Roche for the launch of ELEVIDYS in Japan, it was insufficient to offset the weakness in core product sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194165676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 08:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194165676","market":"nz","top_or_hot":-1,"title":"Stock Track | Sarepta Therapeutics Plunges 5.17% After-Hours on Disappointing Q1 Results and Sharp ELEVIDYS Sales Decline","media":"Stock Track","content":"<p>Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.17% following the release of its first-quarter 2026 financial results.</p><p>While the company reported a positive swing to net income and beat earnings expectations, investors reacted negatively to a 2% year-over-year decline in quarterly revenue to $730.8 million. The decline was primarily driven by a sharp 73% decrease in sales of its flagship gene therapy, ELEVIDYS, which fell to $101.97 million. Overall product revenues dropped 46% to $330.5 million.</p><p>The significant drop in ELEVIDYS demand is attributed to an updated product label that restricts treatment to ambulatory patients, significantly reducing the total addressable market for the therapy. This follows safety events in the previous year and a regulatory crackdown that led to temporary shipment pauses. Despite collaboration revenue growth from milestone payments, including from Roche for the launch of ELEVIDYS in Japan, it was insufficient to offset the weakness in core product sales.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sarepta Therapeutics Plunges 5.17% After-Hours on Disappointing Q1 Results and Sharp ELEVIDYS Sales Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sarepta Therapeutics Plunges 5.17% After-Hours on Disappointing Q1 Results and Sharp ELEVIDYS Sales Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 08:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.17% following the release of its first-quarter 2026 financial results.</p><p>While the company reported a positive swing to net income and beat earnings expectations, investors reacted negatively to a 2% year-over-year decline in quarterly revenue to $730.8 million. The decline was primarily driven by a sharp 73% decrease in sales of its flagship gene therapy, ELEVIDYS, which fell to $101.97 million. Overall product revenues dropped 46% to $330.5 million.</p><p>The significant drop in ELEVIDYS demand is attributed to an updated product label that restricts treatment to ambulatory patients, significantly reducing the total addressable market for the therapy. This follows safety events in the previous year and a regulatory crackdown that led to temporary shipment pauses. Despite collaboration revenue growth from milestone payments, including from Roche for the launch of ELEVIDYS in Japan, it was insufficient to offset the weakness in core product sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"","article_id":"1194165676","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194165676","pubTimestamp":1778112816,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.17% following the release of its first-quarter 2026 financial results.While the company reported a positive swing to net...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics"},"translate_title":"个股追踪|Sarepta Therapeutics盘后暴跌5.17%，Q1业绩令人失望，ELEVIDYS销售额大幅下滑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1},"content_text":"Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.17% following the release of its first-quarter 2026 financial results.While the company reported a positive swing to net income and beat earnings expectations, investors reacted negatively to a 2% year-over-year decline in quarterly revenue to $730.8 million. The decline was primarily driven by a sharp 73% decrease in sales of its flagship gene therapy, ELEVIDYS, which fell to $101.97 million. Overall product revenues dropped 46% to $330.5 million.The significant drop in ELEVIDYS demand is attributed to an updated product label that restricts treatment to ambulatory patients, significantly reducing the total addressable market for the therapy. This follows safety events in the previous year and a regulatory crackdown that led to temporary shipment pauses. Despite collaboration revenue growth from milestone payments, including from Roche for the launch of ELEVIDYS in Japan, it was insufficient to offset the weakness in core product sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194165676","isCrawlerRequest":true}